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The major product secreted by the thyroid is thyroxine (T4), whereas most of the biologi-
cally active triiodothyronine (T3) derives from the peripheral conversion of T4 into T3. The
deiodinase enzymes are involved in activation and inactivation of thyroid hormones (THs).
Type 1 and type 2 deiodinase (D1 and D2) convert T4 into T3 whereas D3 degrades T4
and T3 into inactive metabolites and is thus the major physiological TH inactivator. The
hypothalamic-pituitary-thyroid axis maintains circulatingTH levels constant, while the deio-
dinases tissue-specifically regulate intracellular thyroid status by controlling TH action in a
precise spatio-temporal fashion. Here we review the data related to the recent identifica-
tion of a paraneoplastic syndrome called “consumptive hypothyroidism,” which exemplifies
how deiodinases alter substantially the concentration ofTH in blood.This syndrome results
from the aberrant uncontrolled expression of D3 that can induce a severe form of hypothy-
roidism by inactivatingT4 andT3 in defined tumor tissue.This rareTH insufficiency generally
affects patients in the first years of life, and has distinct features in terms of diagnosis,
treatment, and prognosis with respect to other forms of hypothyroidism.
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INTRODUCTION
Thyroid hormones (THs) are circulating hormones widely
involved in the development and metabolic homeostasis of vir-
tually all mammalian tissues. Alterations in serum TH levels in
the fetus and newborns cause significant deficits in experimental
animals and in humans (1). The importance of maintaining the
TH-dependent transcriptional signature range is supported by the
presence of diverse homeostasis checkpoints. In fact, beyond the
hypothalamus-pituitary-thyroid axis, which responds to changes
in serum levels of thyroid-stimulating hormone (TSH) (2), there
are various ways to affect thyroid status in a specific tissue. First,
TH exerts its genomic action only in tissues that express a thyroid
hormone receptor (TR), and second, it is possible to locally mod-
ulate the amount of TH available for cells at a pre-receptoral level.
TH transporters and deiodinases are important in determining
the availability of TH in a tissue-specific manner.
Although THs are lipophilic molecules, they require spe-
cific plasma membrane transporters to enter target cells. Vari-
ous transporter families have been identified, but only mono-
carboxylate transporters 8 and 10 (MCT8 and MCT10) and
anion transporting polypeptide 1C1 (OATP1C1) have elevated
specificity for THs. These proteins are differentially expressed
in several tissues: OATP1C1 is expressed in liver, kidney, and
brain, MCT8 is highly expressed in liver and brain, and MCT10
is expressed in intestine, kidney, liver, and placenta. A further
level of complexity results from the capacity of these trans-
porters to determine the efflux of THs from the intracellular
environment to the external milieu (3). The clinical relevance
of these transporters is supported by evidence that mutations
in the gene encoding MCT8 are associated with elevated serum
triiodothyronine (T3) levels and severe sex-linked psychomotor
retardation (Allan–Herndon–Dudley syndrome) (4).
Once inside the nucleus, T3 acts through the binding to ligand-
dependent transcription factors namely TRs, which bind, mainly
as heterodimers with retinoid-X receptors, to TH response ele-
ments in target genes (5). TRs are encoded by two genes,THRA and
THRB, which are located on chromosomes 17 and 3, respectively.
TRα has one T3-binding splice product, TRα1, predominantly
expressed in brain, heart, and skeletal muscle, and two non-T3-
binding splice products, TRα2 and TRα3, and several additional
truncated forms. TRβ has three major T3-binding splice prod-
ucts: TRβ1 is almost ubiquitously expressed; TRβ2 is expressed
primarily in the brain, pituitary, retina, and inner ear; and TRβ3
is expressed in kidney, liver, and lung (6).
Selenodeiodinases catalyze the activation (D1 and D2) and
inactivation (D3) of the THs thyroxine (T4) and 3,5,3′-
triiodothyronine (T3) by removing distinct iodine moieties. D1
and D2 convert thyroxine into the most active metabolic form
of TH, T3, by outer ring deiodination; and D3 converts T4 and
T3 into the inactive forms rT3 and 3,3′-diiodiothyronine (T2),
respectively, by inner ring deiodination. D1 is expressed mostly in
the liver, kidney, thyroid, and pituitary; D2 is expressed primar-
ily in the thyroid, central nervous system, pituitary, developing
cochlea, brown adipose tissue, and skeletal muscle; D3 is preva-
lently expressed in many fetal tissues, through the adult it is
expressed in placenta, brain, and skin, and to a lesser extent in
the pregnant uterus and pancreatic B-cells. The three deiodinases
exert different actions: D1 participates in T3 production within
the thyroid gland and controls circulating T3 levels, whereas D2
and D3 are active in local deiodination processes. Recent evidence
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indicates that D1 and D2 are the major sources of circulating T3 in
euthyroid humans, with D1 being the major source of circulating
T3 in hyperthyroid patients (7). Conversely, D3 inactivates T3 at
tissue and plasma level (8). A dramatic example of the potency of
the D3 pathways in TH clearance, at both systemic and tissue level,
is the newly identified consumptive hypothyroidism syndrome,
which is a rare condition resulting from increased D3 production
in neoplastic cells and consequent T4 and T3 catabolism.
In this review, we focus on D3 as the cause of consump-
tive hypothyroidism, a newly recognized clinical entity which
often requires close cooperation between clinical endocrinologists,
pediatricians, and oncologists.
TYPE 3 DEIODINASE AND INACTIVATION OF THYROID
HORMONES
As mentioned, type 3 deiodinase is the physiological inactivator of
TH: it catalyzes deiodination on the inner rings of T3 and T4 to
produce T2 and rT3, respectively. D3 is a selenoenzyme encoded
by the DIO3 gene in humans; it is localized on chromosome 14q32
(9). The DIO3 genomic structure contains a single exon and, at the
3′-UTR, a specific RNA structure, named SECIS (selenocysteine
insertion element), that is crucial for the insertion of the seleno-
cysteine residue and for maximal enzymatic catalytic efficiency
(10). The DIO3 gene is imprinted, with preferential expression of
the paternal allele. It belongs to a cluster of imprinted regions, at
the DLK1-DIO3 locus (11).
D3 is an integral membrane protein that exerts its role as a
homodimer (12). It is recycled through a system of endosomal
clathrin-coated vesicles. This suggests a possible mechanism for
D3 reactivation, and furthermore the possibility that this enzyme
acts on both extracellular and intracellular pools of T3 and T4
(13). Diverse signals are able to regulate D3 expression in vitro
and in vivo: retinoic acid, serum growth factors, estrogens and
progesterone, TGFβ, Wnt-βcatenin, and Shh/Gli2 increase D3 lev-
els, whereas glucocorticoid and growth hormone reduce D3 levels
(14, 15).
Recent data from our laboratory implicates p63, a member
of the p53 family (16), in D3 regulation (unpublished data). D3
plays the essential role of protecting tissue from excessive TH levels
under normal and disease conditions. Indeed, thyrotoxicosis of any
cause induces D3, whereas hypothyroidism suppresses D3 (17). D3
activity is elevated during development, a time when circulating
fetal TH levels are much lower than those of the mother (18).
D3 is widely expressed in such embryonic tissues as liver, cerebral
cortex, cardiovascular apparatus, gonads, gut, skin, and urinary
tract (19). The human placenta also expresses elevated D3 levels.
Within the placenta, D3 blocks the maternal-to-fetal transfer of T4
thereby protecting the fetus from TH excess (20, 21). During late
neonatal and adult life, D3 expression is restricted to a few tissues.
It has been detected in skin, the central nervous system, and some
endocrine glands (22). However, in adult life,D3 expression is reac-
tivated in several disease conditions, namely inflammation, liver
regeneration, cardiac hypertrophy and infarct, and cancer (15, 23–
25). Several studies have demonstrated that thyroid status affects
tumor formation, growth, and metastasis, which suggests that THs
are involved in cell transformation. D3 expression has been widely
documented in a variety of malignancies; it is turned-on in some
malignant cell lines (26) and in a number of human tumors, i.e.,
oligodendromas, astrocytomas, gliosarcomas, glioblastoma multi-
forme, TSH-secreting pituitary adenomas, basal cell carcinomas,
colon adenomas, and carcinomas (25). It has been postulated that
D3 activity is required to facilitate tumor cell proliferation (27).
CONSUMPTIVE HYPOTHYROIDISM
The paraneoplastic syndrome consumptive hypothyroidism is a
rare form of hypothyroidism first identified in newborns with
infantile hepatic hemangiomatosis (HHE) (28). The latter is a
benign tumor of vascular origin affecting 4–5% of white infants.
In most cases, the natural course of HHE is characterized by a
rapid proliferation phase during the first 1–2 years of life, and
by a slow and steady decline over the next 5–7 years until com-
plete spontaneous involution of the tumor mass. The spectrum
of vascular lesions that could be termed “HHE” ranges from
benign and self-limiting to aggressive and life-threatening neo-
plasias. About 10% of cases have aggressive characteristics based
on their size, location, and the number of lesions (29). In 2000,
Huang et al. reported the first case of severe hypothyroidism
(defined as“consumptive hypothyroidism”) in a 6-week-old infant
with HHE (28). At the time of diagnosis, TSH level was elevated
(156 mUI/ml) and the serum free thyroxine (FT4) concentra-
tion was low. Hence, the infant was treated with prednisolone
(2 mg/kg) for the hemangioma, and levothyroxine (LT4) replace-
ment (37.5µg/day) for hypothyroidism, but 16 days later the TSH
value was still 256 mUI/ml. At the age of 3 months, the child had
intermittent bradycardia and hypothermia, which were probably
linked to the hypothyroid status as evidenced by thyroid function
tests. In fact, TSH concentration was 177 mUI/ml, serum T4 con-
centration was 2.5µg/dl, T3 concentration was low (15 ng/ml),
and the level of rT3 was elevated (413 ng/ml). Based on these TH
values, replacement hormone therapy was increased to 50µg/day
of LT4, and intravenous administration of 90µg/day liothyronine
was initiated. This therapy resulted in normalization of TSH and
T3, but T4 levels remained low. This replacement dose of hor-
mone therapy is very high considering that an athyreotic infant of
the same age requires about 7–10µg/kg/day of LT4 (equivalent to
about 3µg/kg/day of T3), which is about nine times lower than
that required by this patient.
After a vertical midline abdominal fasciotomy and emboliza-
tion of the multiple hemangiomas, the patient died from systemic
complications. At that time, the cause of hypothyroidism was not
clear, but a markedly elevated serum thyroglobulin concentration
argued against a diagnosis of congenital hypothyroidism. Fur-
thermore, biochemical TH parameters suggested that THs were
normally synthesized and secreted, but that their rate of degra-
dation was increased. The overexpression of D3 and its activity in
the hemangioma tissue were 0.78 pmol of T3 deiodinated/min/mg
of protein, a value 7.5 times higher than that normally present in
placental tissue, the highest physiological D3-expressing tissue in
humans (20).
To date, more than 20 cases of consumptive hypothyroidism
secondary to neoplasias have been reported (Table 1). An evalu-
ation of all these cases strongly suggests that the development of
consumptive hypothyroidism is related to the elevated D3 enzyme,
which is in turn directly proportional to the size of the tumor
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Table 1 | Summary of published cases of “consumptive hypothyroidism.”
Patient/age Sex Therapy Outcome Reference
At birth F 20µg/kg/day LT4 Spontaneous regression of hemangioma Guven et al. (32)
5µg/kg/day T3 LT4 replacement therapy for 9 months
At birth M – Ligation of the hepatic artery Ayling et al. (35)
LT4 replacement therapy for 9 months
3 week F 25µg/kg/day LT4 Spontaneous regression of hemangioma Mouat et al. (33)
LT4 replacement therapy for 15 months
4 week M 25µg/day LT4 Spontaneous regression of hemangioma Peters et al. (31)
4 week M 112µg/day LT4 Hemangioma recurrence post-pharmacological therapy Kalpatthi et al. (49)
Improvement of thyroid function
6 week F 15µg/kg/day LT4 Liver transplantation Lee et al. (50)
Euthyroid status post-transplantation
6 week M 50µg/day iv/oral LT4 Embolization of hepatic artery Huang et al. (28)
96µg/day iv T3 Dead
7 week M 7µg/kd/day iv LT4 Embolization of hepaticartery Mason et al. (36)
2.5µg/h iv T3
7 week F 7.5µg/kg/day LT4 Hemangioma recurrence post-pharmacological therapy Bessho et al. (51)
Congenital hypothyroidism
8 week F 25µg/day LT4 Dead the day before liver transplantation Ayling et al. (35)
8 week F 2µg/kg/day oral LT4 Hemangioma regression post-pharmacological therapy Vergine et al. (30)
LT4 replacement therapy for 10 months
9 week M 28µg/day LT4 Spontaneous regression of hemangioma Konrad et al. (52)
LT4 replacement therapy for 3 years
11 week M 50µg/day LT4 Embolization Jassam et al. (34)
Dead
4 months F 25µg/day LT4 Ligation of the hepatic artery Balazs et al. (53)
LT4 replacement therapy for 2 years
3 months F 75µg/kg/day iv LT4 Liver transplantation Ayling et al. (35)
20µg/kg/day iv Euthyroid status post-transplantation
T3
4 months F T3 Hemangioma regression post-pharmacological therapy Imteyaz et al. (54)
LT4 replacement therapy for 10 months
8 months M 15µg/kg/day LT4 Spontaneous regression of skin hemangiomas Metwalley et al. (46)
10 months M 120µg/day LT4 Hemangioma regression post-pharmacological therapy Cho et al. (37)
Persistence of hypothyroidism
21 years F 88µg/day oral LT4 Liver transplantation Huang et al. (38)
LT4 replacement therapy for 6 weeks
35 years F 300µg/day oral LT4 Partial hepatectomy Howard et al. (40)
Improvement of hypothyroidism after thyroidectomy
54 years M 1000µg/day oral LT4 Surgical excision of the tumor malignant fibrous Huang et al. (38)
Improvement of hypothyroidism after thyroidectomy
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mass and its specific activity, and independent of its localization.
Furthermore, most cases described so far support the hypothesis
advanced by Huang that D3 activity increases rapidly during the
proliferative phase of hemangioma (28). It is also well recognized
that consumptive hypothyroidism develops when the catabolic
D3 activity exceeds the physiological or exogenous replacement
of THs (Figure 1). The direct relationship between consumptive
hypothyroidism, tumor size, and D3 activity is demonstrated by
the spontaneous remission of hypothyroidism and normalization
of serum rT3 concentration upon the natural regression of HHE
or after surgical resection of the tumor (Table 1).
Recent studies have shed light on the role of D3 in the control of
cell proliferation in tumors. In basal cell carcinoma the constitu-
tive activation of the Shh-Gli pathway directly induces D3 mRNA,
which in turn reduces TH intracellular activity thereby resulting
in increased cyclin D1 expression and keratinocyte proliferation
(15). In colon cancer, D3 is a direct target of β-catenin and its
activation is a key factor in the regulation of cell proliferation in
this tumor (25). Taken together, these findings suggest that local
attenuation of TH is an important step in the primary prolifera-
tion of some neoplastic cells, which might explain the sustained
D3 levels particularly in the initial phase of hemangioma growth.
What induces D3 in hemangioma cells? Data from in vitro stud-
ies suggest that D3 overexpression in hemangioma is induced by
basic fibroblast growth factor and vascular endothelial growth
factor. These angiogenic factors play an important role in the
pathogenesis of hemangioma. Indeed, recent evidence suggests
that propranolol, an antagonist of β2 adrenergic receptors, is able
to block tumor growth by inhibiting the expression of these factors
in endothelial tumor cells (30).
In most cases, HHE responds to treatment with steroids and/or
propanol. If this first-line therapeutic strategy fails, surgery may
be necessary, i.e., tumor resection, liver transplantation, or liga-
tion of the hepatic artery (29). The treatment of HHE-associated
hypothyroidism can problematic because exogenous hormones
are massively converted to inactive forms. The aim of treatment in
such cases is to normalize the T4 level, which is critically important
particularly for the developing brain during the neonatal period.
Hypothyroidism may be very severe, hence large doses of TH
are necessary to normalize the T4 level. Doses of LT4 should be
increased gradually until TH levels normalize. Since T4 is rapidly
converted to the inactive rT3 form, combined therapy with liothy-
ronine may be necessary. Moreover, in severe cases of HHE, par-
enteral LT4 administration, with or without liothyronine, may be
used to bypass the liver and the hemangioma filter (31). Hypothy-
roidism usually resolves with involution of the tumor, and LT4
treatment may be gradually reduced as involution progresses (32,
33). Therefore, thyroid functions must be frequently monitored to
ensure maintenance of the euthyroid status. Monitoring at 6-week
intervals is not sufficient for a rapidly developing condition like
consumptive hypothyroidism, and weekly monitoring of T4 and
T3 levels should be considered particularly in the initial phase of
treatment.
Consumptive hypothyroidism is diagnosed based on the detec-
tion of D3 activity in the tumor tissue of a patient with biochemical
and clinical signs of hypothyroidism. However, HHE biopsy may
be a risky procedure due to the high vascularity of the tumor.
FIGURE 1 | Schematic illustration of the pathogenesis of condition
named “consumptive hypothyroidism.”
Hence, consumptive hypothyroidism should be suspected in each
HHE patient whose TH values rapidly change especially during the
proliferative phase. Usually, the increased D3 activity is mirrored
by an elevation of rT3 level associated with a supraphysiological
requirement for exogenous hormone and an high serum thy-
roglobulin level. In such patients, hypothyroidism usually resolves
after medical or surgical treatment of HHE.
The differential diagnosis is between congenital or acquired
hypothyroidism, TSH-secreting pituitary adenoma and a hor-
mone resistant state. However, a rapid increase of TSH, low levels
of T3 and elevated levels of rT3 associated with rapid proliferation
of a vascular tumor is typical of consumptive hypothyroidism.
Elevated serum thyroglobulin levels, a normal or increased thy-
roid uptake or the presence of thyroid gland verified by ultrasound
can exclude a diagnosis of congenital hypothyroidism (34). Very
rarely, a TSH-like factor may be secreted by HHE, as reported in
one infant with hypothyroidism and HHE (35). In such cases, the
FT4 index is normal in congenital hypothyroidism and elevated in
TSH-secreting pituitary adenomas.
In conclusion, given the long-term negative effects of TH alter-
ations on brain and on overall development, thyroid functions
must be frequently monitored in patients with HHE. Conversely,
since consumptive hypothyroidism has also been described in
two infants with asymptomatic HHE (36, 37), HHE should be
suspected in all infants with severe unexplained hypothyroidism.
Consumptive hypothyroidism has been described also in
adults. The first reported case was a 21-year-old girl with a
large hepatic HHE and hypothyroidism manifested with thyroid
enlargement, a serum TSH concentration of 26.2 mU/L and nor-
mal serum free T4 in the absence of thyroid antibodies (38).
Despite the normal FT4 and total T3 levels, serum rT3 was fivefold
higher than normal without significant illness or liver failure. The
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hypothyroidism and goiter resolved after liver transplantation.
Subsequently, Ruppe et al. (39) reported the first case of con-
sumptive hypothyroidism associated with a “non-vascular tumor”
in an adult who required an elevated dose of LT4 before resec-
tion of a large malignant fibrous tumor. Recently, Howard et al.
described a 38-year-old athyreotic woman who presented elevated
levels of TSH (37.3 mU/L) after the discovery of a large HHE. The
patient also had low T3 and elevated rT3 serum levels (40). An
interesting aspect of this case was an increase in TSH after partial
hepatic resection despite hormone therapy. This may have been
due to the hepatic resection itself. Indeed, regenerative processes
in hepatic tissue are associated with rapid induction of D3 in
post-hepatectomized mice, so one may speculate that hepatic D3
reactivation occurs in humans after liver resection, and this, in
turn, causes an increase in TSH levels (24).
CAN PREGNANCY BE CONSIDERED A MILD FORM OF
“CONSUMPTIVE HYPOTHYROIDISM”?
Pregnancy is a physiological condition characterized by changes in
thyroidal economy due to a combination of pregnancy-related fac-
tors that determine the need for increased TH production. During
pregnancy, thyroid function adapts to the increased concentration
of T4-binding globulin, the effect of chorionic gonadotropin on
maternal thyroid function, the increased requirement of iodine,
and the effect of placental deiodinases on TH concentration. Fetal
thyroid physiology differs greatly from maternal thyroid phys-
iology, but the two systems interact through the placenta and
amniotic fluid. These systems control the transfer of iodine and
TH from the mother to the fetus (41). It is important that an
appropriate amount of TH be transferred from the mother to the
fetus early in gestation because high TH levels are deleterious for
developing fetal tissues (42). Therefore, the transplacental supply
of TH to the fetus must be finely modulated to ensure appropriate
hormone levels. The deiodinases and plasma membrane trans-
porters, which regulate the passage of TH in and out of cells, are
major control mechanisms for transplacental TH passage (20).
Fetal thyroid activity begins in mid gestation, at about 18–
20 weeks. TSH level peaks at 24–28 weeks, with consequent ele-
vated T4 levels at 35–40 weeks (43). T3 levels remain low dur-
ing gestation whereas D3 causes an increase in rT3 levels. High
D3 expression has been found in human placental syncytiotro-
phoblasts and cytotrophoblasts, maternal deciduas, and endothe-
lium of fetal vessels (28). During pregnancy, estrogens are potent
inducers of D3 (14). Elevation of D3 during pregnancy is necessary
to “burn off” the elevated amount of T4 in maternal circulation
and acts as a barrier to maternal-fetal exchanges. The injection
of 700µg of T4 into amniotic fluid of pregnant women at term
caused an increase of about 13-fold in amniotic fluid T3 concen-
tration, and of about 30-fold in rT3 concentration measured 24 h
later (44). Thus, syncytiotrophoblasts, which express high D3 lev-
els, can control the amount and forms of THs taken up by human
placenta.
Further evidence that D3 plays a relevant role in pregnancy is
the finding that at 6–12 weeks of gestation there is a gradient of T4
from the mother to fetus, which is in the opposite direction of the
rT3 gradient. In celomic and amniotic fluid, the concentration of
rT3 is 3.8 and 15 times maternal levels, thereby indicating elevated
D3 activity (45). The D3 activity in the maternal-fetal unit locally
converts most of the T4 derived from the mother into rT3. Low
T4 and T3 levels and a high rT3 level is typical of consumptive
hypothyroidism. Thus, pregnancy could be considered a physio-
logical form of compensated “consumptive hypothyroidism,” in
which the “physiologically increased” expression of D3 increases
the inactivation rate of maternal T4 thereby enhancing the need
for TH.
OTHER CONDITIONS ASSOCIATED WITH ELEVATED D3
LEVELS
Consumptive hypothyroidism has also been associated with extra-
hepatic HHE. In fact, two cases of consumptive hypothyroidism
associated with cutaneous hemangioma have been reported in
infants (40). Moreover, a case of neonatal hemangioma in the skin,
associated with consumptive hypothyroidism, has been reported
in an 8-month-old infant (46). The first case of consumptive
hypothyroidism secondary to a large parotid hemangioma was
reported in 2012 in a child with congenital hypothyroidism and
hypoplastic thyroid gland (47). The first case of consumptive
hypothyroidism from a non-vascular tumor was reported in 2005
in a patient with a large malignant solitary fibrous tumor, express-
ing elevated D3 mRNA, and proteins (39). At diagnosis, the patient
was administered a supraphysiologic dose of levothyroxine prior
to the discovery of the tumor, whose identification suggested that
the cause of hypothyroidism could have been the paraneoplastic
syndrome.
Notably, D3 is frequently overexpressed in malignant cells,
which raises the question“why are circulating TH levels not always
perturbed by neoplastic cells?” It is likely that, in most conditions,
due to the low D3 expression in tumor cells, and more importantly,
to the efficient homeostatic hypothalamic-pituitary-thyroid axis,
paraneoplastic D3 is unable to perturb significantly the circulating
level of TH.
Finally, tyrosine kinase inhibitors have been recently proposed
as therapeutic options for patients with recurrent non-resectable
radio-resistant thyroid cancer. In some of these patients undergo-
ing LT4 replacement therapy, treatment with these drugs has been
associated with an increase in TSH level. This increase has been
associated with the induction (probably at hepatic level) of D3 and,
the consequent need to increase the amount of T4 in replacement
therapy (48).
CONCLUSION
In conclusion, increased catabolism of TH by increased levels of
D3 can cause a rare form of acquired hypothyroidism. While this
rare syndrome was initially described in association with massive
hemangiomas in infants, it was later recognized also in adults, and,
in some cases, as a consequence of non-vascular tumors. Although
this condition is usually reversible, it requires prompt recogni-
tion and immediate TH replacement therapy usually at higher
doses than required in other types of hypothyroidism. Further-
more, given that D3 reactivation in tumors is a rather common
event in the neoplastic context in vitro, and that D3 increase may
be a side effect of new pharmacological treatments, it is conceiv-
able that consumptive hypothyroidism may be more frequent than
expected. For the clinician, this form of hypothyroidism requires
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particular attention given its refractory nature toward replacement
therapy and the risk of mental and growth retardation in neonatal
patients.
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